ES2194320T3 - Sustancias naturales antivirales o antitumorales y uso de las mismas. - Google Patents

Sustancias naturales antivirales o antitumorales y uso de las mismas.

Info

Publication number
ES2194320T3
ES2194320T3 ES98923089T ES98923089T ES2194320T3 ES 2194320 T3 ES2194320 T3 ES 2194320T3 ES 98923089 T ES98923089 T ES 98923089T ES 98923089 T ES98923089 T ES 98923089T ES 2194320 T3 ES2194320 T3 ES 2194320T3
Authority
ES
Spain
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
represented
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98923089T
Other languages
English (en)
Inventor
Tsuneatsu Mori
Maowu Guo
Etsuko Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITOCHU TECHNO CHEM Inc
Original Assignee
ITOCHU TECHNO CHEM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITOCHU TECHNO CHEM Inc filed Critical ITOCHU TECHNO CHEM Inc
Application granted granted Critical
Publication of ES2194320T3 publication Critical patent/ES2194320T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención describe sustancias eficaces contra tumores y virus en los que los agentes convencionales antitumorales y agentes antivirales muestran solamente efectos insuficientes, y que tienen efectos carcinostáticos y efectos antivirales en varios tumores resistentes así como un efecto secundario reducido tal como las células humanas normales que no se han deteriorado.La presente invención se refiere a una sustancia antitumoral o antiviral representada por la fórmula (1)*fórmula*en la que R1 representa un a base de ácido nucleico representada por una fórmula específica, y R2 representa un átomo de hidrógeno, un grupo hidroxilo o un grupo metoxi, o una sal farmacéuticamente aceptable de los mismos.La presente invención también se refiere a un procedimiento para la preparación de una sustancia representada por la fórmula (1) o una sal farmacéuticamente aceptable de la misma, en la que se cultiva la célula NS que tiene la capacidad de producir el compuesto representado en la fórmula(1), el compuesto representado por la fórmula (1) se recoge del cultivo líquido y si es necesario el compuesto se convierte en una sal farmacéuticamente aceptable del mismo.Además, también se describe un compuesto farmacéutico que comprende el compuesto descrito anteriormente como ingrediente eficaz, y célula supresora natural humana positivo -CD57 y fuertemente positivo -HLA.DR-
ES98923089T 1997-06-03 1998-06-02 Sustancias naturales antivirales o antitumorales y uso de las mismas. Expired - Lifetime ES2194320T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15932197 1997-06-03

Publications (1)

Publication Number Publication Date
ES2194320T3 true ES2194320T3 (es) 2003-11-16

Family

ID=15691258

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98923089T Expired - Lifetime ES2194320T3 (es) 1997-06-03 1998-06-02 Sustancias naturales antivirales o antitumorales y uso de las mismas.

Country Status (13)

Country Link
US (1) US6498149B1 (es)
EP (1) EP0997473B1 (es)
JP (1) JP3193061B2 (es)
KR (1) KR100404630B1 (es)
CN (2) CN1292073C (es)
AT (1) ATE236922T1 (es)
AU (1) AU754370B2 (es)
CA (1) CA2294158C (es)
DE (1) DE69813231T2 (es)
ES (1) ES2194320T3 (es)
HK (2) HK1029121A1 (es)
RU (1) RU2205010C2 (es)
WO (1) WO1998055493A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098355C (zh) * 2000-09-12 2003-01-08 华东理工大学 一种乙酰短杆菌及以该菌种为酶源制备5－氟尿苷的方法
CA2434386C (en) * 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2654371A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
BRPI0713901A2 (pt) 2006-06-27 2013-01-08 Biovitrum Ab compostos terapÊuticos
RU2488591C2 (ru) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
FI20096394A0 (fi) 2009-12-23 2009-12-23 Valtion Teknillinen Tunkeutumisen havaitseminen viestintäverkoissa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54129131A (en) * 1978-03-27 1979-10-06 Taiho Pharmaceutical Co Ltd Antiimalignant tumor agent composition
JPS5564518A (en) * 1978-11-07 1980-05-15 Taiho Yakuhin Kogyo Kk Carcinostatic composition
JPS61291595A (ja) * 1985-06-19 1986-12-22 Ajinomoto Co Inc ２′−ｏ−メチル化ｒｎａの製造法
JPS6214794A (ja) * 1985-07-09 1987-01-23 Ajinomoto Co Inc 発酵法によるグアノシン及び／またはイノシンの製造法
JPS6223725A (ja) 1985-07-24 1987-01-31 Sekisui Plastics Co Ltd 熱可塑性樹脂発泡体の製造装置
JPS6223723A (ja) 1985-07-24 1987-01-31 Canon Inc 射出圧縮成形方法
JPH01125325A (ja) * 1987-11-11 1989-05-17 Agency Of Ind Science & Technol 抗腫瘍剤
US5200514A (en) * 1990-01-19 1993-04-06 University Of Georgia Research Foundation, Inc. Synthesis of 2'-deoxypyrimidine nucleosides
JPH0695946B2 (ja) * 1991-01-23 1994-11-30 日本製紙株式会社 ウリジンの製造法
US5580973A (en) 1994-01-07 1996-12-03 Lee-Ruff; Edward Process for preparing optically active nucleosides from chiral cyclobutanones

Also Published As

Publication number Publication date
CA2294158A1 (en) 1998-12-10
EP0997473B1 (en) 2003-04-09
RU2205010C2 (ru) 2003-05-27
CN1616671A (zh) 2005-05-18
AU754370B2 (en) 2002-11-14
AU7549098A (en) 1998-12-21
JP3193061B2 (ja) 2001-07-30
HK1077847A1 (en) 2006-02-24
WO1998055493A1 (fr) 1998-12-10
KR100404630B1 (ko) 2003-11-07
CN1261372A (zh) 2000-07-26
DE69813231T2 (de) 2003-12-04
ATE236922T1 (de) 2003-04-15
EP0997473A4 (en) 2001-01-03
HK1029121A1 (en) 2001-03-23
CN1292073C (zh) 2006-12-27
CA2294158C (en) 2004-11-23
US6498149B1 (en) 2002-12-24
KR20010029544A (ko) 2001-04-06
DE69813231D1 (de) 2003-05-15
CN1195769C (zh) 2005-04-06
EP0997473A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
ES8206488A1 (es) Un procedimiento para preparar compuestos de purina y piri- midina
DE69912313D1 (de) Colchinolderivate als gefässschädigende mittel
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
FI906204A0 (fi) Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi
FI890689A0 (fi) 3-alkenyl-1-azabicyklo-/3.2.0/ -hept-2-en-2-karboxylsyrafoereningar.
PT928788E (pt) Compostos farmaceuticamente activos
CA2014545A1 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
HK1077847A1 (en) Natural antitumor or antiviral substances and use of the same
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
CA2015475A1 (en) Treating agent for osteoarthritis
KR890003382A (ko) 항 비루스성 화합물
DK0437030T3 (da) Anvendelse af 4-substituerede imidazoler til nedsættelse af det intraoculære tryk
HUP0100184A2 (hu) Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ES2046641T3 (es) Composicion antitumoral.
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
CA2035499A1 (en) Substituted triazolopyridazines
DK0911026T3 (da) Creatinderivater for astma
ATE50248T1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
MX9206930A (es) Nuevos compuestos